VistaGen Therapeutics Q1 2025 Adj EPS $(0.35) Beats $(0.41) Estimate, Sales $84.00K Miss $300.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
VistaGen Therapeutics (NASDAQ:VTGN) reported Q1 2025 adjusted EPS of $(0.35), beating the estimate of $(0.41). However, sales were $84.00K, missing the $300.00K estimate and showing a 52.70% decrease from the same period last year.
August 13, 2024 | 8:23 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
VistaGen Therapeutics reported better-than-expected EPS of $(0.35) for Q1 2025, but sales missed estimates significantly at $84.00K, a 52.70% decrease from last year.
While the EPS beat is a positive sign, the significant miss in sales and the year-over-year decline in revenue are concerning. This mixed result is likely to create uncertainty among investors, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100